Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.25    1.10 (14.86%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £59.93m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

Form 8.5 (EPT/RI) - Poolbeg Pharma Plc

14 Feb 2025 10:25

Form 8.5 (EPT/RI) - Poolbeg Pharma Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Shore Capital Stockbrokers Ltd
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereePoolbeg Pharma Plc
(c) Name of the party to the offer with which exempt principal trader is connected:Poolbeg Pharma Plc
(d) Date dealing undertaken:13 February 2025
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?No

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received
OrdinaryPurchases6,9584.8375p4.8375p
OrdinarySalesNANANA

(b) Derivatives transactions (other than option)

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercising

Class of relevant securityProduct description e.g. call optionNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure:14 February 2025
Contact name:Laura Parmenter
Telephone number:0207 647 8154

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
26th May 20227:00 amRNSUS patents granted for POLB 001 and POLB 002
25th May 20224:40 pmRNSSecond Price Monitoring Extn
25th May 20224:35 pmRNSPrice Monitoring Extension
23rd May 20221:01 pmRNSTR-1: Notification of major interest in shares
12th May 20227:00 amRNSGMP manufacturing contract signed
11th May 20227:00 amRNSAttendance at European Melioidosis Congress
27th Apr 20227:00 amRNSDistribution in Specie update
14th Apr 20227:00 amRNSKey POLB 002 European Patent Granted
11th Apr 20227:00 amRNSDistribution in Specie Shareholders
4th Apr 202212:26 pmRNSResult of AGM
31st Mar 20227:00 amRNSPOLB001 Update - Clinical Trial Agreement Signed
30th Mar 20227:00 amRNSCommencement of trading on US OTCQB market
24th Mar 20227:00 amRNSAI deal signed with CytoReason
9th Mar 20227:00 amRNSNotice of AGM
3rd Mar 20227:00 amRNSFinal Results
28th Feb 20227:00 amRNSNotice of Results
24th Feb 20227:00 amRNSArtificial Intelligence deal with OneThree Biotech
31st Jan 20227:00 amRNSConfirmation of vaccine platform licence execution
17th Jan 20227:00 amRNSExclusive license of RNA-based immunotherapy asset
16th Dec 20217:00 amRNSPoolbeg to develop oral vaccine delivery platform
6th Dec 20217:00 amRNSPoolbeg signs option for new vaccine candidate
25th Nov 20217:00 amRNSScientific Advisory Board Appointment
18th Nov 20217:00 amRNSUpdate on POLB 001 Clinical Development
14th Oct 20219:05 amRNSSecond Price Monitoring Extn
14th Oct 20219:00 amRNSPrice Monitoring Extension
14th Oct 20217:00 amRNSPredictViral Patent Update
7th Oct 20217:00 amRNSRNA sequencing ahead of AI analysis programme
13th Sep 20217:00 amRNSSeptember and October Investor conferences
7th Sep 20217:00 amRNSPOLB001 US Patent Update
23rd Aug 20219:06 amRNSSecond Price Monitoring Extn
23rd Aug 20219:00 amRNSPrice Monitoring Extension
4th Aug 202111:30 amRNSHolding(s) in Company
23rd Jul 20211:26 pmRNSTR-1
19th Jul 20217:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.